 Home > Biochemistry News > Biotechnology News > Positive interim data from the first human trial of the second-generation STING agonist for the treatment of solid tumors

Positive interim data from the first human trial of the second-generation STING agonist for the treatment of solid tumors

 Last Update: 2021-07-30
 Source: Internet
 Author: User

Tags

ranolazine dose

pd 1 pd l1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, F-star Therapeutics announced the interim results of its second-generation STING agonist SB 11285 in the first human dose escalation study
.

This clinical trial aims to evaluate the safety and efficacy of intravenous infusion of SB 11285 as a single agent or in combination with the anti-PD-L1 monoclonal antibody atezolizumab in the treatment of patients with advanced solid tumors

STING is a transmembrane protein located in the endoplasmic reticulum of the cell, which plays a key role in the immune system's production of type I interferon against pathogens
.

Studies have shown that the activation of STING is associated with a long-lasting anti-cancer immune response

F-Star’s SB 11285 differs from the first-generation STING agonist in that it can be delivered systemically, allowing the drug to be delivered to difficult-to-reach tumors
.

Moreover, SB 11285 may promote the migration of activated immune cells from the periphery to tumor lesions

Image source: F-Star company official website

The interim results of the phase 1 clinical trial showed that SB 11285, as a single agent, showed good tolerability at the five doses that have been evaluated so far, and the three dose groups used in combination with atezolizumab also showed good tolerability.

The preliminary pharmacokinetic analysis results are consistent with the rapid absorption of SB 11285 by cells

Note: The original text has been deleted

Reference materials:

[1] F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.